Insight Molecular Diagnostics
IMDX
65 hedge funds and large institutions have $48.4M invested in Insight Molecular Diagnostics in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 23 reducing their positions, and 14 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.11% less ownership
Funds ownership: 2.9% → 2.79% (-0.11%)
13% less funds holding
Funds holding: 75 → 65 (-10)
22% less capital invested
Capital invested by funds: $61.9M → $48.4M (-$13.5M)
57% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 23
64% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$36.4K |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$27.8K |
| 3 |
Jane Street
New York
|
+$26.6K |
| 4 |
LPL Financial
San Diego,
California
|
+$26K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$18.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$827K |
| 2 |
Millennium Management
New York
|
-$238K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$194K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$180K |
| 5 |
E
Ergoteles
New York
|
-$145K |
IMDX Hedge Fund Activity: Q3 2022 in Review
65 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q3 2022, worth a combined $48.4M — down 22% from $61.9M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of IMDX and 5 opened new positions — a net loss of 9 holders — while 23 trimmed existing stakes and 10 added.
The largest buyer was Balyasny Asset Management, adding an estimated $36.4K. The largest seller was OrbiMed, cutting an estimated $827K.
- 65 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q3 2022, down from 75 in Q2 2022.
- Funds reported $48.4M of Insight Molecular Diagnostics stock for Q3 2022, down 22% quarter-over-quarter.
- 5 funds opened new Insight Molecular Diagnostics positions in Q3 2022 and 14 closed out, a net change of -9 holders.
- The largest Insight Molecular Diagnostics buyer in Q3 2022 was Balyasny Asset Management, an estimated $36.4K added.
- The largest Insight Molecular Diagnostics seller in Q3 2022 was OrbiMed, an estimated $827K sold.
Based on aggregated 13F filings for Q3 2022.